Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 6/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | FLT3 | P36888 | 1/20 | 0.30 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.30 |
| ▸ | MERTK | Q12866 | 1/20 | 0.30 |
| ▸ | GAS6 | Q14393 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13558788 | 0.81 | BACE1 (0.48) | BACE1RXFP1 | |
| SCHEMBL7512910 | 0.78 | BACE1 (0.43) | BACE1NPC1RAB9ANAMPTSMN1; SMN2 | |
| SCHEMBL14643204 | 0.75 | HDAC6 (0.40) | BACE1NPC1RAB9ASMN1; SMN2RXFP1 | |
| SCHEMBL13558819 | 0.72 | BACE1 (0.41) | BACE1NAMPTUSP2 | |
| SCHEMBL7526815 | 0.69 | BACE1 (0.46) | BACE1USP2 | |
| SCHEMBL7518509 | 0.68 | HDAC6 (0.47) | BACE1RXFP1 | |
| SCHEMBL7510083 | 0.68 | BACE1 (0.50) | BACE1NPC1RAB9ASMN1; SMN2USP2 | |
| SCHEMBL7536228 | 0.67 | BACE1 (0.44) | BACE1NAMPTPOLB | |
| SCHEMBL7526737 | 0.67 | BACE1 (0.49) | BACE1NPC1RAB9ANAMPTHTT | |
| SCHEMBL7514490 | 0.66 | BACE1 (0.50) | BACE1NAMPTUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120276118-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | PHARMACOPEIA INC. (US) | 2012-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120276118-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | BACE1, PRSS1, TMPRSS11D | BACE1 1/4885NPC1 649/4885RAB9A 3578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.